Patents by Inventor Tsung-Huang Tsai

Tsung-Huang Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250243282
    Abstract: Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
    Type: Application
    Filed: April 18, 2025
    Publication date: July 31, 2025
    Inventors: Dongxu Sun, Catherine A. Gordon, Ksenya Shchors, Yan Wang, Tsung-Huang Tsai, Yew Ann Leong
  • Publication number: 20250145722
    Abstract: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
    Type: Application
    Filed: January 10, 2025
    Publication date: May 8, 2025
    Inventors: Dongxu Sun, Suhail Rasool, Catherine A. Gordon, Ke Hong, Fan Chen, Sara Matilda Bolin, Ksenya Shchors, Yadong Yu, Tsung-Huang Tsai, Samuel A.F. Williams, Karan Lala, Heng Wu, Yan Wang
  • Patent number: 12281166
    Abstract: Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
    Type: Grant
    Filed: May 25, 2021
    Date of Patent: April 22, 2025
    Assignee: TrueBinding, Inc.
    Inventors: Dongxu Sun, Catherine A. Gordon, Ksenya Shchors, Yan Wang, Tsung-Huang Tsai, Yew Ann Leong
  • Publication number: 20230094463
    Abstract: Disclosed herein are methods and compositions for disrupting an interaction between Galectin-3 and insulin receptor or integrins. Further disclosed herein are methods and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of diabetes mellitus, inflammatory bowel syndrome, non-alcoholic fatty liver disease, and nonalcoholic steatohepatitis.
    Type: Application
    Filed: December 3, 2020
    Publication date: March 30, 2023
    Inventors: Dongxu Sun, Jing Zhang, Maja Bonacorsi, Yinan Wu, Yadong Yu, Catherine A. Gordon, Tsung-Huang Tsai, Ksenya Shchors, Samuel A.F. Williams
  • Publication number: 20230036181
    Abstract: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and/or proteins associated with neurological diseases and/or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and/or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.
    Type: Application
    Filed: July 12, 2022
    Publication date: February 2, 2023
    Inventors: Dongxu Sun, Suhail Rasool, Catherine A. Gordon, Ke Hong, Fan Chen, Sara Matilda Bolin, Ksenya Shchors, Yadong Yu, Tsung-Huang Tsai, Samuel A.F. Williams, Karan Lala, Heng Wu, Yan Wang
  • Publication number: 20210371533
    Abstract: Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.
    Type: Application
    Filed: May 25, 2021
    Publication date: December 2, 2021
    Inventors: Dongxu Sun, Catherine A. Gordon, Ksenya Shchors, Yan Wang, Tsung-Huang Tsai, Yew Ann Leong